NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”) (NASDAQ: STSS), a medical device company with a Solana (SOL) digital asset treasury strategy, and BitGo Bank & Trust, National Association (“BitGo”), the digital asset infrastructure company, today announced a strategic collaboration under which STSS will expand and further institutionalize its Solana treasury strategy through BitGo’s services. As part of this arrangement, STSS intends to utilize BitGo’s institutio ...

NEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (“STSS” or the “Company”), a medical device company implementing a Solana-based digital asset treasury strategy, today issued an update on its treasury and recent operational highlights. Treasury Updates Staking: Since inception, STSS’s validator partners have generated ~7% gross annual percentage yield (APY) before fees, outperforming the Solana network average. Nearly all of the Company’s SOL holdings are currently staked.Balance Sheet: S ...

NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (NASDAQ: STSS) today announced that it has entered into a 90-day lock-up agreement with SOL Markets (the “Strategic Advisor”), pursuant to which SOL Markets has agreed to restrict sales of its advisory warrants and any underlying shares. The lock-up reflects strong conviction in STSS’s execution roadmap and reinforces alignment between the parties. This comes after the company's recent announcement that its Board of Directors approved a sha ...

Core Insights - Sharps Technology (STSS) has expanded its relationship with Coinbase Institutional by launching a jointly supported institutional-grade validator on the Solana network [1] - STSS will delegate a portion of its SOL treasury holdings, which exceed 2 million SOL, to the newly established Coinbase-operated validator [1] - The collaboration aims to leverage Coinbase's institutional-grade infrastructure and security standards to ensure high uptime and operational reliability [1] Company Summary - Sharps Technology (STSS) is enhancing its operational capabilities through a partnership with Coinbase Institutional [1] - The company is focusing on the Solana network for its validator operations, indicating a strategic move towards blockchain technology [1] - The partnership is expected to improve the reliability and performance of STSS's validator operations [1]

Core Viewpoint - Sharps Technology, Inc. is expanding its partnership with Coinbase Institutional by launching an institutional-grade validator on the Solana network, marking a significant shift in its role from a participant in digital asset treasury strategies to directly contributing to network security and decentralization [1][3]. Group 1: Partnership and Validator Launch - The new validator, operated by Coinbase, represents an important transition for the company, allowing it to delegate part of its SOL treasury assets to this newly established validator [3]. - The company currently holds over 2 million SOL, and this collaboration integrates Coinbase's institutional-grade infrastructure and operational expertise to ensure high operational stability and reliability of the validator [3]. Group 2: Strategic Implications - The launch of the STSS validator is seen as an extension of the company's involvement in the development and security of the Solana network, leveraging Coinbase's operational capabilities [4]. - With the validator's launch, the company becomes one of the first publicly traded U.S. companies to evolve from merely adopting digital asset treasury strategies to actively participating in blockchain infrastructure development [4]. Group 3: Company Overview - Sharps Technology is an innovative medical device and pharmaceutical packaging company focused on providing patented technology and industry-leading smart safety syringe products, emphasizing ultra-low waste in consumables [5]. - The company's digital asset treasury strategy focuses on accumulating SOL and generating on-chain yields within the Solana ecosystem through capital market financing [5].

Core Viewpoint - Sharps Technology, Inc. is expanding its relationship with Coinbase Institutional by launching an institutional-grade validator on the Solana network, marking a significant shift from being a treasury participant to an active contributor to the network's security and decentralization [1][2]. Group 1: Company Strategy - The company will delegate a portion of its SOL treasury holdings, which currently exceed 2 million SOL, to the newly established Coinbase-operated validator [3]. - This initiative builds on the existing relationship with Coinbase Institutional, leveraging its custody, OTC, and operational infrastructure as part of the broader digital asset treasury strategy [4]. Group 2: Industry Impact - The launch of the STSS Validator positions the company as one of the first U.S.-listed firms to transition from a treasury-only approach to an active participant in blockchain development [5]. - The partnership with Coinbase aims to enhance the security, compliance, and operational reliability of institutional-grade infrastructure, reflecting the growing trend of institutions moving on-chain [5]. Group 3: Company Background - Sharps Technology is a medical device and pharmaceutical packaging company that offers patented smart-safety syringe products, focusing on ultra-low waste capabilities and incorporating advanced safety features [9]. - The company has adopted a digital asset treasury strategy centered on accumulating SOL, the native digital asset of the Solana blockchain, to generate on-chain yield [10].

Core Insights - Several small-cap biotech and healthcare companies experienced notable gains in after-hours trading, driven by recent corporate updates and clinical milestones Company Updates - Inspira Technologies Oxy B.H.N. Ltd. (IINN) rose 5.88% to $1.08 following a recent definitive agreement for a registered direct offering of its ordinary shares and a Standby Equity Purchase Agreement with YA II PN, Ltd. [2] - Galectin Therapeutics Inc. (GALT) increased by 1.79% to close at $6.27, despite no new corporate developments reported [3] - MediciNova, Inc. (MNOV) advanced 4.83% to $1.52 after successfully completing patient enrollment in its Phase 2 OXTOX study, evaluating MN-166 for chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients [4] - Marker Therapeutics, Inc. (MRKR) gained 5.56% to $1.33 without any new company-specific announcements [5] - Sharps Technology, Inc. (STSS) climbed nearly 4% to $2.09, also without fresh updates [6] - DiaMedica Therapeutics Inc. (DMAC) rose 2.89% to $8.55 after a productive pre-IND meeting with the FDA regarding its planned study of DM199 in preeclampsia [6] - Corbus Pharmaceuticals Holdings, Inc. (CRBP) edged higher by 1.36% to $8.21, following the completion of its Phase 1a study of CRB-913 and initiation of the Phase 1b CANYON-1 trial [7] - ProMIS Neurosciences, Inc. (PMN) added 0.83% to $8.49, recovering slightly after a decline earlier in the day, with the completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial for Alzheimer's disease [8]

Core Insights - Sharps Technology, Inc. has reported transformative financial results for Q3 2025, highlighting a strong balance sheet bolstered by a Solana-based treasury strategy and a successful $411 million PIPE financing [2][4] Financial Performance - The company raised gross proceeds of $411 million through a PIPE, consisting of $267 million in cash and stablecoins and $144 million in SOL [8] - As of October 31, 2025, Sharps holds over 2.0 million SOL in its treasury, generating approximately $17.7 million in combined staking revenue and digital-asset fair-value gains during Q3 [8] - Cash and stablecoin liquidity stood at approximately $25.2 million as of September 30, 2025 [8] Strategic Initiatives - The company has exited legacy syringe manufacturing, streamlining operations and reducing costs, allowing it to focus on two strategic priorities: medical device sales and distribution, and maximizing the value of its SOL-based digital asset treasury [8] - Management aims to optimize yields across its Solana ecosystem holdings and leverage capital markets access for long-term growth [4][8] Market Position - The adoption of a Solana-based treasury strategy and the resulting financial strength position Sharps Technology to pursue viable business strategies and deliver long-term value for shareholders [2][4]

Financial Performance - The company reported a net loss of $105.3 million for the three months ended September 30, 2025, primarily due to stock compensation charges and asset impairments [205]. - Selling, General and Administrative expenses surged to $110,719,156, a 5,822% increase from $1,869,598 in the same quarter of 2024, largely due to stock compensation expenses [243]. - For the three months ended September 30, 2025, the Company recognized product revenue of $83,622, primarily from Sologard syringes sold under a supply agreement [238]. - The Company reported net staking revenue of $2,205,423 for the same period, resulting from its digital treasury platform [240]. - For the nine months ended September 30, 2025, the company reported net revenue of $306,344, primarily from the sale of Securegard and Sologard syringes under a supply agreement with Stericare [250]. - The company recognized net staking revenue of $2,205,423 during the same period, resulting from its digital treasury platform [252]. - Selling, General and Administrative expenses surged to $114,571,809, a 2,079% increase from $5,257,015 in the prior year, largely due to realized and unrealized gains on digital assets amounting to $15,499,742 [255]. Cash Flow and Liquidity - As of September 30, 2025, the company used $11.7 million in cash for operations and had current cash of $10.5 million and USDC of $14.7 million, indicating sufficient liquidity for planned operations over the next twelve months [206]. - Cash used in operating activities was $11,743,528 for the nine months ended September 30, 2025, compared to $5,172,135 in the prior year, primarily due to increased transaction fees and higher G&A expenses [264]. - Cash used in investing activities increased significantly to $189,506,025, mainly due to the purchase of digital assets of $186,104,214 following the August 2025 offering [265]. - Cash provided by financing activities reached $210,726,915, a substantial increase from $5,707,946 in the previous year, driven by net proceeds from offerings [267]. - The company had a working capital of $29,045,025 as of September 30, 2025, a significant improvement from a working capital deficiency of $2,011,679 at the end of 2024 [260]. Strategic Direction - The company will no longer engage in research and development activities following the Settlement Agreement, focusing instead on marketing and distribution of syringe products [210]. - The company has begun exploring strategic acquisitions and investments globally, hiring a Head of Innovation to analyze opportunities [212]. - The company intends to explore plans to expand its distribution platform by representing established third-party manufacturers of complementary medical products [233]. Asset Management - The company adopted a treasury policy allocating principal holdings to digital assets, specifically Solana (SOL), with over 2.0 million SOL held as of October 31, 2025 [211]. - The Company adopted a digital asset treasury strategy focused on accumulating SOL, the native digital asset of the Solana blockchain [234]. - The company stakes a portion of its SOL holdings to earn staking rewards, with an expected un-staking period of approximately 48 hours under normal conditions [281]. - The Company recorded a realized and unrealized gain of $15,499,742 on digital assets during the quarter [244]. - The company recorded a foreign currency gain of $371,741, reflecting a 1,278% increase compared to a loss of $31,566 in the previous year [259]. - An impairment of long-lived fixed assets was recorded at $7,497,669, reflecting the fair market value of assets related to the pending sale of the Safegard subsidiary [245]. - The company recorded a net asset impairment of $7,497,669 related to the fair market value of fixed assets due to the pending sale of the Safegard subsidiary [256]. Research and Development - The company recognized research and development expenses primarily related to syringe products, which will cease due to the new strategic direction [210]. - Research and Development expenses decreased to $295,579, down 44% from $523,347 in the prior year, due to a shift towards increased manufacturing [254]. Risks and Considerations - Digital assets held through custodians do not generally enjoy the same regulatory protections as cash or securities deposited with FDIC or SIPC [280]. - Use of derivatives such as call and put options may require margin posting, potentially reducing available liquidity and introducing additional volatility [282]. - Exposure to SOL introduces various risks including market risk, liquidity risk, operational risk, regulatory risk, accounting risk, and concentration risk [283].

Partnership & Strategy - Pudgy Penguins 与 Sharps Technology 合作，探索 NFT 和链上资金库策略的整合 [1] - 合作旨在通过结合 NFT 资产与链上资金库策略，提高品牌知名度并促进机构采用 [1] - Sharps Technology (纳斯达克上市公司) 将其基于 Solana 的资金库系统与 Pudgy Penguins 品牌整合 [1]